-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target

Benzinga·08/21/2026 19:06:34
Listen to the news
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.